Showing 1 - 3 results of 3 for search 'Emilie Desfleurs', query time: 0.02s Refine Results
  1. 1
    Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France

    Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of... by Maxime Dougados, Pascal Claudepierre, Adeline Ruyssen-Witrand, Philippe Goupille, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas, Julien Lucas, Emilie Desfleurs

    Published 2022-03-01
    Get full text
    Article
  2. 2
    Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)

    Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA) by Maxime Dougados, Pascal Claudepierre, Adeline Ruyssen-Witrand, Philippe Goupille, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas, Julien Lucas, Emilie Desfleurs

    Published 2023-03-01
    Get full text
    Article
  3. 3
    Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study

    Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospectiv... by Maxime Dougados, Pascal Claudepierre, Philippe Goupille, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas, Adeline Ryussen-Witrand, Emilie Desfleurs, Audrey Lardy-Cleaud

    Published 2024-02-01
    Get full text
    Article

Search Tools: